



09/03/04

1FW

Docket 17684 (AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lyons, Robert T. et al.,

Serial No.: 10/826,843

Filed: 4/15/2004

For: DRUG DELIVERY TO THE BACK
OF THE EYE

Examiner:

Group Art Unit: 1614

Irvine, California

INFORMATION DISCLOSURE STATEMENT

Mailstop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled DRUG DELIVERY TO THE BACK OF THE EYE, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 2 page Information Disclosure Citation (Form PTO-1449).


While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material

documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: September 1, 2004



Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date September 1, 2004, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EL979880612US addressed to Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Bartholomew
Name of person mailing paper



Signature of person signing paper

Date September 1, 2004

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17684(AP)	SERIAL NO.: 10/826,843
APPLICANT: Lyons, Robert T. et al.,	TITLE: DRUG DELIVERY OT THE BACK OF THE EYE
FILING DATE: 04/15/2004	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
AA	60/289,337		Lyons, Robert T.			5/7/2001
AB	60/098,854		Beck et al.			9/2/1998
AC	60/289,337		Lyons, Robert T.			5/7/2001
AD	2002/0012680	1/31/2002	Patel et al.			
AE	2002/0035264	3/21/2002	Kararli et al.			
AF	2002/0055496	5/9/2002	McCoy et al.			
AG	2002/0076449	6/20/2002	Beck et al.			
AH	2002/0198174	12/26/2002	Lyons, Robert T.			
AI	2003/0027790	2/6/2003	Singh et al.			
AJ	2003/0109492	6/12/2003	Loftsson,T.			
AK	2004/0019012	1/29/2004	Singh et al.			
AL	3,459,731	8/5/1969	Gramera et al.			
AM	4,383,992	5/17/1983	Lipari, John M.			
AN	4,877,774	10/31/1989	Pitha et al.			
AO	5,024,998	6/18/1991	Bodor, Nicholas S.			
AP	5,068,226	11/26/1991	Weinshenker et al.			
AQ	5,134,127	7/28/1992	Stella et al.			
AR	5,227,372	7/13/1993	Folkman, Judah			
AS	5,229,370	7/20/1993	Ammeraal, Robert			
AT	5,324,718	6/28/1994	Loftsson, T.			
AU	5,376,641	12/27/1994	Ammeraal, Robert			
AV	5,376,645	12/27/1994	Stella et al.			
AW	5,472,954	12/5/1995	Loftsson, T.			
AX	5,576,311	11/19/1996	Guy, Yaacov			
AY	5,587,175	12/24/1996	Viegas et al.			
AZ	5,747,061	5/5/1998	Amselem et al.			
AAA	5,760,017	6/2/1998	Djedaini-Pilard et al			
ABB	6,358,935	3/19/2002	Beck et al.			
ACC	6,407,079	6/18/2002	Muller et al.			
ADD	6,468,548	10/22/2002	Kis, Gyorgy			

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17684(AP)	SERIAL NO.: 10/826,843
APPLICANT: Lyons, Robert T. et al.,	TITLE: DRUG DELIVERY OT THE BACK OF THE EYE
FILING DATE: 04/15/2004	GROUP: 1614

	AEE	6,495,120	12/17/2002	McCoy et al.			
	AFF	6,696,426	2/24/2004	Singh et al.			
	AGG	6,723,353	4/20/2004	Beck et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	EP0435682	7/3/1991	EPO			Y
	BB	EP0 579435	1/19/1994	EPO			Y
	BC	EP 0794783 B1	9/17/1997	EPO			Y
	BD						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Hirayama, F. et al.; <i>Methods of Investigating and Preparing inclusion Compounds</i> ; Chapter 4 of <i>Cyclodextrins and their industrial uses</i> ; Editor Dominique Duchene; Paris
CB	Jansen et a.; Beta-Cyclodextrins as Vehicles in Eye-Drop Formulations: An <i>Evaluation of their Effects on Rabbit Corneal Epithelium</i> ; Lens and Eye Toxicity Research, 7(3&4), 459-468, 1990
CC	Loftsson et al.; <i>Interactions Between Preservatives and 2-Hydroxypropyl-B-Cyclodextrin</i> ; Drug Development and Industrial Pharmacy, 18(13), 1477-1484; 1992
CD	Rajewski & Stella; <i>Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery</i> ; Journal of Pharmaceutical Sciences, Vol. 85, No. 11, 1142-1169, Nov 1996
CE	Sadlej-Sosnowska, Nina; <i>Influence of the Structure of Steroid Hormones on Their Association with Cyclodextrins: A High-Performance Liquid Chromatography Study</i> ; <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 27; 31-40, 1997
CF	Zhao, L. et al.; <i>Predicting Solubility in Multiple Nonpolar Drugs-Cyclodextrin System</i> ; Journal of Pharmaceutical Sciences, Vol. 91, No. 11, Nov 2002; pp 2301-2306
CG	
CH	
CI	
CJ	
CK	

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.